

## Contents

**Contributors** *xxi*  
**Preface** *xxiii*  
**Acknowledgments** *xxv*

### **Part I Principles of Veterinary Psychopharmacology** 1

- 1 General Principles of Psychopharmacology** 3  
*Thomas F. Murray*  
Drug Action 3  
Dose Dependence of Drug Interaction with Receptors 4  
Structural Features of the Central Nervous System (CNS) and Neurotransmission 5  
Biogenic Amine Neurotransmitters and Affective Disorders 8
- 2 Amino Acid Neurotransmitters: Glutamate, GABA, and the Pharmacology of Benzodiazepines** 11  
*Thomas F. Murray*  
Introduction 11  
Glutamatergic Synapses 11  
Pharmacology of Ketamine and Tiletamine 14  
GABAergic Synapses 15
- 3 Biogenic Amine Neurotransmitters: Serotonin** 21  
*Thomas F. Murray*  
Introduction 21  
The Biogenic Amines 21  
Serotonin 22
- 4 Biogenic Amine Transmitters: Acetylcholine, Norepinephrine, and Dopamine** 29  
*Thomas F. Murray*  
Acetylcholine 29  
Norepinephrine 32  
Dopamine 37
- 5 Neuropeptides: Opioids and Oxytocin** 43  
*Thomas F. Murray*  
Introduction 43  
Endogenous Opioid Peptides 43  
Oxytocin 47

**Part II Practice of Veterinary Psychopharmacology 51****6 Introduction to Clinical Psychopharmacology for Veterinary Medicine 53***Sharon L. Crowell-Davis and Leticia Mattos de Souza Dantas*

Introduction 53

Prescribing in the United States: The Animal Medicinal Drug Use Clarification Act (AMDUCA 1994) 54

Cost 55

Drug Selection 56

Medicating the Patient 57

Competition Animals 58

Taking the Behavioral History 58

The Behavioral Exam 63

Duration of Treatment 63

Limitations 64

**7 Benzodiazepines 67***Leticia Mattos de Souza Dantas and Sharon L. Crowell-Davis*

Action 67

Overview of Indications 67

Contraindications, Side Effects, and Adverse Events 69

Overdose 69

Clinical Guidelines 69

Specific Medications 71

I. Alprazolam 71

Clinical Pharmacology 71

Uses in Humans 72

Contraindications 72

Side Effects 72

Overdose 72

Doses in Nonhuman Animals 72

Discontinuation 72

Other Information 72

Effects Documented in Nonhuman Animals 73

II. Chlordiazepoxide HCl 73

Clinical Pharmacology 73

Uses in Humans 74

Contraindications 74

Side Effects 74

Overdose 75

Doses in Nonhuman Animals 75

Discontinuation 75

Other Information 75

Effects Documented in Nonhuman Animals 75

III. Clonazepam 76

Clinical Pharmacology 76

Uses in Humans 76

|  |    |
|--|----|
| Contraindications                      | 76 |
| Side Effects                           | 77 |
| Drug Interactions                      | 77 |
| Overdose                               | 77 |
| Doses in Nonhuman Animals              | 77 |
| Discontinuation                        | 77 |
| Other Information                      | 77 |
| Effects Documented in Nonhuman Animals | 77 |
| IV. Clorazepate Dipotassium            | 78 |
| Clinical Pharmacology                  | 78 |
| Uses in Humans                         | 79 |
| Contraindications                      | 79 |
| Side Effects                           | 79 |
| Dependence                             | 79 |
| Overdose                               | 79 |
| Doses in Nonhuman Animals              | 79 |
| Effects Documented in Nonhuman Animals | 79 |
| V. Diazepam                            | 80 |
| Clinical Pharmacology                  | 80 |
| Uses in Humans                         | 82 |
| Contraindications                      | 82 |
| Side Effects                           | 82 |
| Overdose                               | 83 |
| Doses in Nonhuman Animals              | 83 |
| Discontinuation                        | 83 |
| Other                                  | 83 |
| Effects Documented in Nonhuman Animals | 84 |
| VI. Flurazepam Hydrochloride           | 86 |
| Clinical Pharmacology                  | 86 |
| Uses in Humans                         | 87 |
| Contraindications                      | 87 |
| Side Effects                           | 87 |
| Overdose                               | 87 |
| Doses in Nonhuman Animals              | 87 |
| Effects Documented in Nonhuman Animals | 87 |
| VII. Lorazepam                         | 87 |
| Clinical Pharmacology                  | 87 |
| Uses in Humans                         | 88 |
| Contraindications                      | 88 |
| Side Effects                           | 89 |
| Overdose                               | 89 |
| Doses in Nonhuman Animals              | 89 |
| Discontinuation                        | 89 |
| Effects Documented in Nonhuman Animals | 89 |
| VIII. Oxazepam                         | 89 |
| Clinical Pharmacology                  | 89 |
| Uses in Humans                         | 90 |
| Contraindications                      | 90 |

- Side Effects 90
- Overdose 90
- Doses in Nonhuman Animals 90
- Discontinuation 91
- Other Information 91
- Effects Documented in Nonhuman Animals 91
- IX. Triazolam 91
  - Clinical Pharmacology 91
  - Uses in Humans 91
  - Contraindications 91
  - Side Effects 91
  - Overdose 92
  - Doses in Nonhuman Animals 92
  - Effects Documented in Nonhuman Animals 92
- Important Information for Owners of Pets Being Placed on Any Benzodiazepine 92

**8 Selective Serotonin Reuptake Inhibitors 103**

*Niwako Ogata, Leticia Mattos de Souza Dantas, and Sharon L. Crowell-Davis*

- Action 103
- Overview of Indications 103
- Contraindications, Side Effects, and Adverse Events 104
- Adverse Drug Interactions 104
- Overdose 105
- Clinical Guidelines 105
- Specific Medications 106
  - I. Citalopram Hydrobromide 106
    - Clinical Pharmacology 106
    - Uses in Humans 106
    - Contraindications 106
    - Side Effects 106
    - Overdose 107
    - Other Information 107
    - Effects Documented in Nonhuman Animals 107
  - II. Fluoxetine Hydrochloride 108
    - Clinical Pharmacology 108
    - Uses in Humans 108
    - Contraindications 108
    - Side Effects 109
    - Overdose 110
    - Doses in Nonhuman Animals 110
    - Discontinuation of Fluoxetine 110
    - Other Information 110
    - Effects Documented in Nonhuman Animals 110
  - III. Fluvoxamine 115
    - Clinical Pharmacology 115
    - Uses in Humans 115
    - Contraindications 115
    - Side Effects 116

|   |     |
|---|-----|
| Overdose  | 116 |
| Other Information   | 116 |
| Effects Documented in Nonhuman Animals                            | 116 |
| IV. Paroxetine Hydrochloride                                      | 117 |
| Clinical Pharmacology   | 117 |
| Uses in Humans  | 117 |
| Contraindications   | 117 |
| Side Effects  | 118 |
| Overdose  | 119 |
| Discontinuation of Paroxetine                                     | 119 |
| Other Information   | 119 |
| Effects Documented in Nonhuman Animals                            | 119 |
| V. Sertraline Hydrochloride                                       | 119 |
| Clinical Pharmacology   | 119 |
| Uses in Humans  | 120 |
| Contraindications   | 120 |
| Side Effects  | 120 |
| Other Information   | 121 |
| Effects Documented in Nonhuman Animals                            | 121 |
| VI. Escitalopram Oxalate  | 122 |
| Clinical Pharmacology   | 122 |
| Uses in Humans  | 122 |
| Contraindications   | 122 |
| Side Effects  | 123 |
| Overdose  | 123 |
| Other Information   | 123 |
| Effects Documented in Nonhuman Animals                            | 123 |
| Important Information for Owners of Pets Being Placed on Any SSRI | 124 |

## 9 Miscellaneous Serotonergic Agents 129

*Leticia Mattos de Souza Dantas and Sharon L. Crowell-Davis*

Introduction 129

Azapirones 129

    Action 129

    Overview of Indications 129

    Contraindications, Side Effects, and Adverse Events 129

    Adverse Drug Interactions 129

    Overdose 129

    Clinical Guidelines 129

Specific Medications 130

I. Bupirone 130

    Clinical Pharmacology 130

    Uses in Humans 131

    Contraindications 131

    Side Effects 131

    Overdose 131

    Other Information 131

    Effects Documented in Nonhuman Animals 132

|  |            |
|--|------------|
| Serotonin Antagonist/Reuptake Inhibitors (SARIs)                                   | 135        |
| Action   | 135        |
| Overview of Indications  | 135        |
| Contraindications, Side Effects, and Adverse Events                                | 135        |
| Adverse Drug Interactions  | 135        |
| Overdose   | 135        |
| Clinical Guidelines  | 135        |
| Specific Medications   | 135        |
| I. Trazodone Hydrochloride   | 135        |
| Clinical Pharmacology  | 135        |
| Uses in Humans   | 137        |
| Contraindications  | 137        |
| Side Effects   | 137        |
| Overdose   | 137        |
| Other Information  | 138        |
| Effects Documented in Nonhuman Animals   | 138        |
| <b>10 Anticonvulsants and Mood Stabilizers</b>                                     | <b>147</b> |
| <i>Sharon L. Crowell-Davis, Mami Irimajiri, and Leticia Mattos de Souza Dantas</i> |            |
| Action   | 147        |
| Overview of Indications  | 148        |
| Clinical Guidelines  | 148        |
| Specific Medications   | 148        |
| I. Carbamazepine   | 148        |
| Clinical Pharmacology  | 149        |
| Side Effects   | 149        |
| Effects in Non-human Animals   | 149        |
| II. Gabapentin   | 149        |
| Clinical Pharmacology  | 149        |
| Uses in Humans   | 150        |
| Contraindications  | 150        |
| Side Effects   | 150        |
| Overdose   | 150        |
| Doses in Nonhuman Animals  | 150        |
| Other Information  | 150        |
| Effects Documented in Non-human Animals  | 151        |
| Cattle   | 151        |
| III. Pregabalin  | 152        |
| Clinical Pharmacology  | 152        |
| Uses in Humans   | 153        |
| Side Effects   | 153        |
| Effects Documented in Nonhuman Animals   | 153        |
| <b>11 Sympatholytic Agents</b>   | <b>157</b> |
| <i>Niwako Ogata and Leticia Mattos de Souza Dantas</i>                             |            |
| Action   | 157        |
| Overview of Indications  | 157        |
| Contraindications, Side Effects, and Adverse Events                                | 158        |

|  |     |
|--|-----|
| Overdose                               | 159 |
| Clinical Guidelines                    | 159 |
| Specific Medications                   | 160 |
| I. Clonidine                           | 160 |
| Clinical Pharmacology                  | 160 |
| Uses in Humans                         | 160 |
| Contraindications                      | 160 |
| Side Effects                           | 161 |
| Other Information                      | 161 |
| Effects Documented in Nonhuman Animals | 161 |
| II. Detomidine                         | 161 |
| Clinical Pharmacology                  | 161 |
| Use in Humans                          | 162 |
| Contraindications                      | 162 |
| Side Effects                           | 162 |
| Other Information                      | 162 |
| Effects Documented in Nonhuman Animals | 162 |
| III. Dexmedetomidine                   | 163 |
| Clinical Pharmacology                  | 163 |
| Use in Humans                          | 163 |
| Contraindications                      | 163 |
| Side Effects                           | 164 |
| Effects Documented in Nonhuman Animals | 164 |
| IV. Propranolol                        | 165 |
| Clinical Pharmacology                  | 165 |
| Use in Humans                          | 165 |
| Contraindications                      | 165 |
| Side Effects                           | 165 |
| Effects Documented in Nonhuman Animals | 166 |

## 12 N-Methyl-D-Aspartate (NMDA) Receptor Antagonists 171

|  |     |
|--|-----|
| <i>Niwako Ogata and Leticia Mattos de Souza Dantas</i> |     |
| Action   | 171 |
| Overview of Indications                                | 172 |
| Contraindications/Side Effects, and Adverse Events     | 172 |
| Clinical Guidelines                                    | 173 |
| Specific Medications                                   | 173 |
| I. Dextromethorphan                                    | 173 |
| Clinical Pharmacology                                  | 174 |
| Contraindications and Side Effects                     | 174 |
| Other Information                                      | 174 |
| Effects Documented in Nonhuman Animals                 | 174 |
| Horses   | 175 |
| II. Amantadine   | 175 |
| Clinical Pharmacology                                  | 175 |
| Use in Humans  | 175 |
| Contraindications                                      | 175 |

|   |            |
|---|------------|
| Side Effects  | 175        |
| Overdose  | 176        |
| Effects Documented in Nonhuman Animals                            | 176        |
| III. Memantine  | 176        |
| Clinical Pharmacology   | 176        |
| Use in Humans   | 177        |
| Side Effects  | 177        |
| Other Information   | 177        |
| Effects Documented in Nonhuman Animals                            | 178        |
| IV. Huperzine A   | 179        |
| Clinical Pharmacology   | 179        |
| Use in Humans   | 179        |
| Overdose and Side Effects   | 179        |
| Effects Documented in Nonhuman Animals                            | 179        |
| <b>13 Monoamine Oxidase Inhibitors</b>                            | <b>185</b> |
| <i>Leticia Mattos de Souza Dantas and Sharon L. Crowell-Davis</i> |            |
| Action  | 185        |
| Overview of Indications   | 186        |
| Specific Medications  | 186        |
| I. Selegiline Hydrochloride                                       | 186        |
| Clinical Pharmacology   | 186        |
| Uses in Humans  | 187        |
| Contraindications   | 187        |
| Side Effects  | 188        |
| Overdose  | 188        |
| Discontinuation   | 188        |
| Other Information   | 188        |
| Effects Documented in Nonhuman Animals                            | 190        |
| <b>14 Antipsychotics</b>  | <b>201</b> |
| <i>Lynne Seibert and Sharon Crowell-Davis</i>                     |            |
| Introduction  | 201        |
| Action  | 201        |
| Overview of Indications   | 202        |
| General Pharmacokinetics  | 203        |
| Contraindications, Side Effects, and Adverse Events               | 203        |
| Overdose  | 203        |
| Clinical Guidelines   | 204        |
| Specific Medications  | 204        |
| I. Acepromazine Maleate   | 204        |
| Clinical Pharmacology   | 204        |
| Indications   | 204        |
| Contraindications   | 204        |
| Side Effects  | 204        |
| Adverse Drug Interactions   | 205        |
| Overdose  | 205        |
| Doses in Nonhuman Animals   | 205        |
| Effects Documented in Nonhuman Animals                            | 205        |

- II. Azaperone 206
  - Clinical Pharmacology 206
  - Indications 206
  - Doses in Nonhuman Animals 206
- III. Chlorpromazine 206
  - Clinical Pharmacology 206
  - Uses in Humans 207
  - Indications in Veterinary Medicine 207
  - Contraindications 207
  - Side Effects 207
  - Effects Documented in Nonhuman Animals 207
- IV. Clozapine 207
  - Clinical Pharmacology 207
  - Uses in Humans 207
  - Contraindications 207
  - Side Effects 207
  - Doses in Nonhuman Animals 208
  - Effects Documented in Nonhuman Animals 208
- V. Fluphenazine 208
  - Clinical Pharmacology 208
  - Contraindications and Side Effects 208
  - Effects Documented in Nonhuman Animals 208
- VI. Haloperidol 209
  - Clinical Pharmacology 209
  - Uses in Humans 209
  - Contraindications 209
  - Side Effects 209
  - Overdose 209
  - Doses in Nonhuman Animals 209
  - Effects Documented in Nonhuman Animals 209
- VII. Pimozide 210
  - Clinical Pharmacology 210
  - Uses in Humans 210
  - Contraindications 210
  - Side Effects 211
  - Doses in Nonhuman Animals 211
  - Effects Documented in Nonhuman Animals 211
- VIII. Promazine 211
  - Clinical Pharmacology 211
  - Indications 211
  - Contraindications 211
  - Side Effects 211
- IX. Sulpiride 211
  - Clinical Pharmacology 211
  - Uses in Humans 212
  - Contraindications 212
  - Side Effects 212
  - Doses in Nonhuman Animals 212
  - Effects Documented in Nonhuman Animals 212

- X. Thioridazine 212
  - Clinical Pharmacology 212
  - Uses in Humans 213
  - Contraindications 213
  - Side Effects 213
  - Doses in Nonhuman Animals 213
  - Effects Documented in Nonhuman Animals 213
- Important Information for Owners of Pets Being Placed on an Antipsychotic 213
- 15 CNS Stimulants 217**
  - Sharon L. Crowell-Davis*
  - Action 217
  - Overview of Indications 217
  - Contraindications, Side Effects, and Adverse Events 217
  - Adverse Drug Interactions 217
  - Overdose 217
  - Clinical Guidelines 218
  - Specific Medications 219
    - I. Amphetamine 219
      - Clinical Pharmacology 219
      - Uses in Humans 220
      - Contraindications 220
      - Side Effects 220
      - Overdose 220
      - Discontinuation 220
      - Other Information 220
      - Effects Documented in Nonhuman Animals 220
      - Other Species 221
    - II. Atomoxetine HCl 221
      - Clinical Pharmacology 221
      - Uses in Humans 222
      - Contraindications 222
      - Side Effects 222
      - Overdose 222
      - Discontinuation 222
      - Other Information 223
      - Effects Documented in Nonhuman Animals 223
    - III. Methylphenidate Hydrochloride 223
      - Clinical Pharmacology 223
      - Uses in Humans 224
      - Contraindications 224
      - Side Effects 224
      - Overdose 225
      - Doses in Nonhuman Animals 225
      - Discontinuation 226
      - Other Information 226
      - Effects Documented in Nonhuman Animals 226

Important Information for Owners of Pets Being Placed on CNS Stimulants 226

Clinical Examples 227

Case 1 227

Signalment 227

Presenting Complaint 227

History 227

Diagnosis 227

Treatment Plan 227

Follow-Up 227

## 16 Tricyclic Antidepressants 231

*Sharon L. Crowell-Davis*

Action 231

Overview of Indications 231

Contraindications, Side Effects, and Adverse Events 232

Adverse Drug Interactions 232

Overdose 232

Discontinuation 233

Clinical Guidelines 233

Specific Medications 233

I. Amitriptyline 233

Clinical Pharmacology 234

Uses in Humans 234

Contraindications 234

Side Effects 234

Overdose 235

Discontinuation 235

Other Information 235

Effects Documented in Nonhuman Animals 235

II. Clomipramine Hydrochloride 236

Clinical Pharmacology 236

Uses in Humans 237

Contraindications 237

Side Effects 238

Overdose 238

Discontinuation 238

Effects Documented in Nonhuman Animals 238

III. Desipramine 243

Clinical Pharmacology 243

Uses in Humans 243

Contraindications 243

Side Effects 243

Overdose 244

Effects Documented in Nonhuman Animals 244

IV. Doxepin 244

Clinical Pharmacology 244

Uses in Humans 245

- Contraindications 245
- Side Effects 245
- Overdose 245
- Effects Documented in Nonhuman Animals 245
- V. Imipramine 246
  - Clinical Pharmacology 246
  - Uses in Humans 246
  - Contraindications 246
  - Side Effects 246
  - Overdose 247
  - Effects Documented in Nonhuman Animals 247
- VI. Nortriptyline 248
  - Clinical Pharmacology 248
  - Uses in Humans 248
  - Contraindications 248
  - Side Effects 248
  - Overdose 248
  - Effects Documented in Nonhuman Animals 248
- Important Information for Owners of Pets Being Placed on any TCA 248

**17 Opioids and Opioid Antagonists 257**

*Leticia Mattos de Souza Dantas and Sharon L. Crowell-Davis*

- Action 257
- Overview of Indications 257
- Contraindications, Side Effects, and Adverse Events 258
- Clinical Guidelines 258
- Specific Medications 258
  - I. Nalmefene 258
    - Clinical Pharmacology 258
    - Uses in Humans 259
    - Contraindications 259
    - Side Effects 259
    - Other Information 259
    - Effects Documented in Nonhuman Animals 259
  - II. Naloxone HCl 260
    - Clinical Pharmacology 260
    - Uses in Humans 260
    - Contraindications 260
    - Side Effects 260
    - Overdose 260
    - Doses in Nonhuman Animals 261
    - Discontinuation 261
    - Effects Documented in Nonhuman Animals 261
  - III. Naltrexone Hydrochloride 261
    - Clinical Pharmacology 261
    - Uses in Humans 262
    - Contraindications 262

|  |     |
|--|-----|
| Side Effects                           | 262 |
| Overdose                               | 262 |
| Discontinuation                        | 262 |
| Other Information                      | 262 |
| Uses Documented in Nonhuman Animals    | 262 |
| IV. Pentazocine                        | 264 |
| Clinical Pharmacology                  | 264 |
| Uses in Humans                         | 264 |
| Contraindications                      | 264 |
| Side Effects                           | 265 |
| Overdose                               | 265 |
| Discontinuation                        | 265 |
| Other Information                      | 265 |
| Effects Documented in Nonhuman Animals | 265 |

## 18 Hormones 269

*Sharon L. Crowell-Davis*

Introduction 269

Oxytocin 270

    Clinical Pharmacology 270

    Indications 270

    Side Effects 270

    Doses in Nonhuman Animals 270

    Effects Documented in Nonhuman Animals 270

Progestins 270

    Action 270

    Overview of Indications 271

    Contraindications, Side Effects, and Adverse Events 271

    Overdose 271

    Clinical Guidelines 272

Specific Medications 272

I. Medroxyprogesterone Acetate (MPA) 272

    Clinical Pharmacology 272

    Uses in Humans 272

    Contraindications 272

    Side Effects 272

    Adverse Drug Interactions 272

    Effects Documented in Nonhuman Animals 272

II. Megestrol Acetate 273

    Clinical Pharmacology 273

    Uses in Humans 273

    Contraindications 273

    Adverse Drug Interactions 273

    Side Effects 273

    Overdose 274

    Effects Documented in Nonhuman Animals 274

**19 Combinations 281**

*Leticia Mattos de Souza Dantas, Sharon L. Crowell-Davis, and Niwako Ogata*

Introduction 281

Overview of Drug Augmentation 281

Potentially Beneficial Combinations 282

Adverse Interactions and Contraindications 283

Changing and Weaning Patients off Medications 285

Cytochrome P450 (CYP) 285

Interactions That Can Affect Dosing 285

Algorithms: Possible Future Direction 286

Conclusion 288

**Index 291**